Form 4: Corcept Therapeutics Executive William Guyer Exercises Options, Sells Shares Under 10b5-1 Plan
SEC Form 4
William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On September 3, 2024, William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $21.65 per share.
- Simultaneously, Guyer sold 10,000 shares of Corcept Therapeutics common stock at $35.30 per share.
- These transactions were executed under a pre-existing 10b5-1 trading plan.
- 243 shares were withheld by the issuer to satisfy tax obligations related to the vesting of restricted stock units.
- Following these transactions, Guyer directly owns 5,796 shares of Corcept Therapeutics common stock, which includes 609 unvested restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider transactions. It's common for executives to use 10b5-1 plans to sell shares periodically to avoid accusations of trading on inside information. The exercise of options and subsequent sale can provide the executive with liquidity while diversifying their holdings.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedules and exercise prices are typical for such arrangements.
- The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations, similar to practices at companies like Gilead Sciences or Amgen.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- Shareholders may view insider sales with caution, but the use of a 10b5-1 plan mitigates concerns about opportunistic trading.
Key Dates
| Date | Description |
|---|---|
| August 16, 2021 | Vesting Commencement Date for stock options. |
| December 1, 2023 | Date of grant for restricted stock units, vesting 100% on the one-year anniversary. |
| August 30, 2024 | Closing price used to calculate withholding obligation. |
| September 03, 2024 | Date of stock option exercise and share sale. |
| September 01, 2031 | Expiration date of the stock options. |
| September 05, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.